Clinical trial
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in…
NCT00375726 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00375726 |
|---|---|
| Title | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults |
| Official title | Phase 1 Study of the Safety and Immunogenicity of rDEN3/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3 |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Johns Hopkins Bloomberg School of Public Health |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Dengue |
| Intervention type | Biological |
| Interventions | rDEN3/4delta30(ME), Placebo |
| Enrollment | 58 |
| Start date | Oct 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Sep 13, 2006 |
| Last update posted | Dec 14, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: